trimebutine maleate / Generic mfg. - LARVOL DELTA

Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. (PubMed, Int J Mol Sci) - "Trimebutine, a gastrointestinal motility regulator targeting G-protein-coupled receptors (GPCRs), was identified as a potent agent with over 49.5-fold higher selectivity toward lung CSC-like cells (SI > 49.55) compared with standard therapies such as cisplatin (SI = 1.39) and gefitinib (SI = 1.00). In combination with cisplatin, trimebutine exhibited strong synergistic efficacy (Chou-Talalay combination index, CI = 0.015-0.228) in H460-SP spheres and patient-derived lung tumor organoids, suppressing cell viability, stemness marker suppression, and apoptotic cleavage of caspase-3 and PARP compared to monotherapies. Overall, trimebutine targets lung CSC populations by disrupting GPCR-ion channel-Hippo signaling crosstalk, providing a strong preclinical rationale for trimebutine-cisplatin combination strategies to overcome drug resistance and recurrence in lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor • BMI1 • CACNA1B • CACNA1E • CACNA1H • CACNG3 • CASP3 • CD133 • EPCAM • KCNH2 • MYC • NANOG • SMAD3 • SOX2

LEVELS OF CHOLECYSTOKININ AND MOTILIN IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS (INCLUDING IRRITABLE BOWEL SYNDROME): EFFECT OF TRIMEBUTINE THERAPY (UEGW 2026) - No abstract available

Clinical • Gastroenterology • Gastrointestinal Disorder

Low-Molecular-Weight Peptides from Musca domestica Larvae Alleviate Diarrhea-Predominant Irritable Bowel Syndrome Comorbid with Depression via Regulating Gut Microbiota, Short-Chain Fatty Acids and Serum Metabolism. (PubMed, Int J Mol Sci) - "CACS triggered typical comorbid symptoms, which LMWPs alleviated with effects similar to trimebutine maleate...Multi-omics correlation analyses suggested that the therapeutic benefits may involve crosstalk among gut microbiota, SCFAs, and tryptophan metabolites. Larva-derived LMWP relieves IBS-D combined with depression by modulating gut microecology, SCFA generation and serum metabolic balance through the gut-brain axis, which can serve as a novel promising therapeutic candidate."

Journal • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Effects of Biling Weitong granules on gastrointestinal motility and gastrointestinal hormones levels in rats with functional dyspepsia. (PubMed, J Tradit Chin Med) - "Biling Weitong granules can modulate the levels of the gastrointestinal hormones MTL and VIP in FD rats, promote gastric emptying and small intestinal propulsion, improve the gastrointestinal motility and mental status of FD rats, and alleviate the symptoms of FD, accounting for its efficacy against FD."

Journal • Preclinical • Dyspepsia • MLN

Trimebutine Maleate for Enhancing Gastric Visualization in Acute Upper Gastrointestinal Bleeding (clinicaltrials.gov) - P2/3 | N=100 | Not yet recruiting | Sponsor: Assiut University

New P2/3 trial • Gastroenterology • Hematological Disorders

Esomeprazole plus trimebutine maleate improves symptoms, esophageal function, and acid control without increasing risks in elderly GERD: a real-world retrospective study. (PubMed, Am J Transl Res) - "Adding TM to EMZ improves symptom control, esophageal motility, acid exposure, and inflammatory markers in elderly GERD patients without compromising safety."

Journal • Real-world evidence • Retrospective data • Gastroenterology • Gastroesophageal Reflux Disease

Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome (clinicaltrials.gov) - P3 | N=106 | Not yet recruiting | Sponsor: Nanjing First Hospital, Nanjing Medical University

New P3 trial • Gastrointestinal Disorder

CHRONIC KIDNEY DISEASE AND ACUPUNCTURE: AN UNEXPECTED TURNAROUND (ERA 2026) - "The patient was able to discontinue all home medications (sodium bicarbonate, ebastine, pantoprazole, famotidine, macrogol, treoli, rizmoic, trimebutine, pyridostigmine, rifaximin/VSL, normast, bisacodyl, glycerin, senna, buprenorphine) retaining only clonazepam. Why this case is exeptional In summary, this case demonstrates that acupuncture may provide meaningful clinical benefits in patients with CKD who experience refractory symptoms, supporting its consideration as a complementary approach in nephrology care. Table Laboratory Parameters and Medications Changes in a patient treated with Acupuncture Baseline (March 2025) Session VII (July 2025) Follow-up (Jan 2026) sCreat (mg/dL) 2.19 1.68 1.96 Urea (mg/dL) 74 64 79 eGFR (mL/min) 25 35 28 Total sProtein (g/dL) 7.3 7.1 6.9 Uprot (mg/day) 675 693 800 UUrea (g/die) 10 14.4 13.2 Hb (g/dL) 13.4 13.6 13.1 HCO3 (mmol/L) 21 28 21 Total N. Medications 16 1 3 Image TE6 point needling for treating constipation"

Cardiovascular • Chronic Kidney Disease • Constipation • Endometriosis • Gastroenterology • Gastrointestinal Disorder • Gynecology • Inflammation • Metabolic Disorders • Movement Disorders • Musculoskeletal Pain • Nephrology • Renal Disease

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Valenta Pharm JSC

New P3 trial • Gastroenterology • Gastrointestinal Cancer • Hepatology • Movement Disorders

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Valenta Pharm JSC

New P1 trial • Gastroenterology • Hepatology • Movement Disorders

Efficacy and mechanism of multi-strain probiotic intervention in patients with irritable bowel syndrome: a randomised, double-blind, placebo-controlled trial (ChiCTR) - P=N/A | N=116 | Sponsor: Peking University Third Hospital; Peking University Third Hospital

New trial • Gastrointestinal Disorder

Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study. (PubMed, Medicina (Kaunas)) - " The data validate trimebutine's profile as a well-tolerated and efficacious therapy for patients with IBS in real-world clinical practice in Bulgaria. The findings endorse the prospective inclusion of trimebutine as a treatment option in forthcoming clinical guidelines."

Clinical • Journal • P4 data • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Pain

Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome. (PubMed, Turk J Gastroenterol) - "However, there is a lack of high-quality data for drugs like alverine, trimebutine, and cimetropium, and some drugs, such as simeticone or combinations of spasmolytic agents and simeticone, have insufficient research data. Clinicians should prioritize evidence-based medicine when selecting antispasmodic agents."

Journal • Review • Gastrointestinal Disorder

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Valenta Pharm JSC

New P1 trial • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hepatology • Movement Disorders

THE EFFECT OF VISCERAL SENSITIVITY ON THE COURSE OF THE IRRITABLE INTESTINE SYNDROME (UEGW 2025) - "The first group received the SNRI antidepressant (duloxetine) 60 mg/day, while the second group received trimebutine maleate 600 mg/day for 8 weeks, followed by assessment of therapy effectiveness. The effectiveness of therapy in the first group of patients was associated with the severe course of IBS, characterized by high gastrointestinal anxiety, abdominal pain, and low VST. In the overall group, post-treatment correlation analysis revealed a connection between the severity of clinical presentation and VST levels (BDT). Balloon dilatation test allows an objective assessment of IBS severity and therapeutic effectiveness."

Gastrointestinal Disorder • Immunology • Mood Disorders • Musculoskeletal Pain • Psychiatry

RESULTS OF A MULTICENTER STUDY ON THE IMPACT OF COMBINATION THERAPY WITH RIFAXIMIN AND TRIMEBUTINE ON QUALITY OF LIFE AND DISEASE COURSE IN UNCOMPLICATED DIVERTICULAR DISEASE IN REAL CLINICAL PRACTICE (ALLIANCE) (UEGW 2025) - "The combination of rifaximin and trimebutine reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease without the development of any serious adverse events and adverse reactions."

Clinical • Combination therapy • HEOR • Constipation • Gastrointestinal Disorder • Inflammatory Bowel Disease

Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients. (PubMed, Am J Transl Res) - "Combined therapy with OB and TM-906 is a safe and effective treatment for IBS, offering quicker symptom relief and substantial improvement in quality of life."

Journal • Gastrointestinal Disorder

Massive peritoneal effusion following hip arthroscopy: a case report and review of the literature. (PubMed, J Med Case Rep) - "Large peritoneal effusion after hip arthroscopy is a rare but serious complication that can lead to intra-abdominal hypertension. Surgeons should be careful, especially in patients with prior abdominal surgeries or prolonged procedures near the iliopsoas tendon sheath, and take preventive measures such as minimizing perfusion pressure and monitoring vital signs."

Journal • Anesthesia • Cardiovascular • Hypertension • Orthopedics

ER stress genes (COL1A1, LOXL2, VWF) predicts IKK-16 as a Candidate therapeutic target for colitis-related inflammation and fibrosis suppression. (PubMed, Front Immunol) - "The predicted drugs were ranked based on their binding affinities as follows: IKK-16 > Quercetin > Curcumin > Resveratrol > Budesonide > Trimebutine > Colchicine > Betamethasone > Pioglitazone > Metformin. IKK-16 shows promise as a therapeutic agent. These findings provide new insights into UC pathogenesis and potential clinical treatment strategies."

Journal • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • COL1A1 • MZB1

Steatotic liver disease in patients with irritable bowel syndrome- a new category? Evidence based on response to therapy (EASL 2025) - "Patients received treatment with trimebutine maleate 300mg daily and a probiotic containing Saccharomyces cerevisiae for three months and were re-evaluated... Rapid changes in degrees of steatosis and fibrosis under IBS treatment suggest common pathological pathways between IBS and SLD and potential reversal in the early stages."

Clinical • Constipation • Fibrosis • Gastrointestinal Disorder • Hepatology • Immunology • Solid Tumor

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Valenta Pharm JSC

New P2 trial • Gastroenterology • Hepatology • Movement Disorders

Probiotics Combined With Trimebutine for the Treatment of Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis. (PubMed, J Gastroenterol Hepatol) - "The combination of trimebutine and probiotics is more effective in the treatment of IBS compared with trimebutine alone."

Journal • Retrospective data • Gastrointestinal Disorder • Xerostomia

PET imaging of the anticancer drug candidate [11C]trimebutine in a rat glioma model. (PubMed, Nucl Med Biol) - "Trimebutine exhibits inhibitory effects on the growth and migration of glioma cells in a dose- and time-dependent manner. [11C]Trimebutine was able to penetrate the blood-brain barrier in rats and tracer uptake could be significantly reduced by administration of a μ-opioid receptor antagonist. However, [11C]trimebutine failed to selectively accumulate in orthotopic C6 glioma, which could be caused by low expression levels of the drug target in these tumors, or by fast metabolism of the tracer."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Turmeric - not just health benefits. A case report on Turmeric related Drug Induced Liver Injury (DILI) (EUSEM 2024) - "We would like to present a patient with Drug Induced Liver Injury (DILI) after consuming 'health shots' containing ginger and turmeric/curcuma.Case report28-year-old female with PMHx of colon irritable with simethicone and trimebutine if needed treatment, and oral contraception...She had jaundice, her cardiopulmonary examination was normal, the abdomen as soft with normal bowel sounds, she had some URQ tenderness, no guarding or mass was found. Her bloods showed normal NFS, RFT and coagulation with TP 95%, but abnormal LFT with minor cytolysis with ALAT 247 U/l (ref"

Case report • Clinical • Hepatology • Liver Failure

Novel Combination Therapy for Heart Failure: Trimebutine-Methoxsalen Identified through Synergistic Network Virtual Screening and Experimental Validation. (PubMed, J Chem Inf Model) - "Further mechanistic studies have demonstrated that trimebutine and methoxsalen could synergistically inhibit intracellular calcium overload in myocardial cells and reduce the production of ROS, thus exerting cardioprotective effects. Overall, this study introduces an advanced computational strategy that not only identifies a novel combination therapy against HF but also sheds light on its underlying synergistic mechanisms."

Combination therapy • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure